Clinical Trials · NCT05194124

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Name: Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Setmelanotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 19
Start date: Dec 2021
Locations: 7 sites, 6 countries
Primary endpoint: Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period

View Setmelanotide compound reference